ongoing trials trial from www.clinicaltrials.gov Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy Year: 2025 Date: 2024-06 Author: Study design (if review, criteria of inclusion for studies) INTERVENTIONAL - Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT Participants Cystic Fibrosis-related Diabetes - CHILD, ADULT, OLDER_ADULT Interventions DEVICE: iLet Bionic Pancreas System (BP)|DEVICE: Usual Care (UC) Outcome measures CGM-measured Time In Target Range of 70-180 mg/dL (TIR), CGM-measured time in target range of 70-180 mg/dL (TIR), 13 weeks Related topics Pancreatic enzyme replacement therapy in cystic fibrosis